Amylyx Pharmaceuticals Faces Multiple Securities Fraud Lawsuits

Investors allege misleading statements regarding ALS treatment RELYVRIO's commercial prospects and prescription rates.

Multiple law firms have filed class action lawsuits against Amylyx Pharmaceuticals, alleging securities fraud related to its ALS treatment, RELYVRIO.
The lawsuits claim Amylyx made false statements about RELYVRIO's commercial prospects and prescription rates.
Investors were misled as Amylyx allegedly overstated the demand for RELYVRIO and concealed declining patient continuation rates.
The legal actions follow Amylyx's announcement of disappointing financial results for Q3 2023, which led to a significant drop in its stock price.
Investors have until April 9, 2024, to file lead plaintiff applications in the securities class action lawsuits.